

101 Federal Street, Suite 1900 #10 Boston, Massachusetts 02110-1821 508-865-8907 <u>info@eclinicalresearchconsulting.com</u> <u>http://www.eclinicalresearchconsulting.com</u>

Principal Investigator Education Program Online Course Agenda

(rev. August, 2006)

PRINCIPAL INVESTIGATOR EDUCATION PROGRAM

Online Course Agenda

Module 1

The Drug Development Process

- 1. The Goal of Clinical Research
- 2. Preclinical and Clinical Research
- 3. Phases of Clinical Research
- 4. The Process of Developing a Drug through Clinical Research
- 5. Common Obstacles

Module 2

The Role of the Principal Investigator

- 1. What is a Principal Investigator (PI)?
- 2. FDA Form 1572
- 3. Principal Investigator Responsibilities
- 4. GCP Guidelines for Investigators

Module 3

Informed Consent

- 1. What is Informed Consent?
- 2. FDA Requirements (Sample ICF Review)
- 3. Developing and Informed Consent Form

Module 4

The Clinical Research Protocol

- 1. FDA/GCP Requirements
- 2. Working with the Clinical Research Protocol
- 3. Protocol Deviations
- 4. Protocol Compliance
- 5. Creating Tools that Aid in Protocol Adherence

Module 5

Understanding Adverse Events

- 1. What is an Adverse Event
- 2. What is a Serious Adverse Event
- 3. Documenting and Reporting Adverse Events
- 4. IND Safety Reports

Module 6

Source Documentation

- 1. What are Source Documents?
- 2. Examples of Source Documents Used in Clinical Research
- 3. How to Maintain Adequate Source Documentation
- 4. What are Sponsor Companies Looking For?

Module 7

Essential Documents

- 1. What are Essential Documents?
- 2. GCP Guidelines for Essential Documents
- 3. Maintaining Essential Documents
- 4. Communicating and Corresponding with the IRB

Module 8

Non-Compliance, Fraud and FDA Suspension

- 1. What is Noncompliance?
- 2. What is Fraud?
- 3. Why the FDA may Disqualify an Investigator
- 4. FDA Disqualification Process
- 5. An Example of an FDA Warning Letter
- 6. Clinical Investigator Inspection List, FDA Investigator Disqualification List, List of Assurances Accepted for Future Performance of Studies with Investigational Product

Appendix 1:

FDA Regulations in Clinical Research

Title 21 CRF – Food and Drug Administration

- 1. CFR Part 11: Electronic Records; Electronic Signatures
- 2. CFR Part 50: Protection of Human Subjects
- 3. CFR Part 54: Financial Disclosure by Clinical Investigators
- 4. CFR Part 56: Institutional Review Boards
- 5. CFR Part 312: Investigational New Drug Application
- 6. CFR Part 314: Application for FDA Approval to Market a New Drug
- 7. CFR Part 320: Bioavailability and Bioequivalence Requirements
- 8. CFR Part 601: Licensing
- 9. CFR Part 812: Investigational Device Exemptions
- 10. CFR Part 814: Premarket Approval of Medical Devices

Appendix 2:

Guidance for Industry E6 Good Clinical Practice Consolidated Guidance ICH 1996

- 1. Introduction
- 2. Glossary
- 3. The Principles of ICH GCP
- 4. IRB/IEC
- 5. Investigator
- 6. Sponsor
- 7. Clinical Trial Protocol
- 8. Investigator's Brochure
- 9. Essential Documents

Appendix 3:

Sample Informed Consent Form